Literature DB >> 9422358

Arginine and lysine aminopeptidase activities in chromaffin granules of bovine adrenal medulla: relevance to prohormone processing.

S Yasothornsrikul1, T Toneff, S R Hwang, V Y Hook.   

Abstract

Conversion of prohormones and neuropeptide precursors to smaller, biologically active peptides requires specific proteolytic processing at paired basic residues, which generates intermediate peptides with NH2 and COOH termini extended with Lys or Arg residues. These basic residues are then removed by aminopeptidase and carboxypeptidase activities, respectively. Among the proteases involved in prohormone processing, the basic residue aminopeptidase activity has not been well studied. This report demonstrates arginine and lysine aminopeptidase activities detected with Arg-methylcoumarinamide (Arg-MCA) and Lys-MCA substrates in neurosecretory vesicles of bovine adrenal medulla [chromaffin granules (CG)], which contain endoproteolytic processing enzymes co-localized with [Met]enkephalin and other neuropeptides. These arginine and lysine aminopeptidase activities showed many similarities and some differences. Both arginine and lysine aminopeptidase activities were stimulated by the reducing agent beta-mercaptoethanol (beta-ME) and inhibited by p-hydroxymercuribenzoate, suggesting involvement of reduced cysteinyl residues. The arginine aminopeptidase activity was stimulated by NaCl (150 mM), but the lysine aminopeptidase activity was minimally affected. Moreover, characteristic beta-ME/NaCl-stimulated Arg-MCA cleaving activity and beta-ME-stimulated Lys-MCA cleaving activity were detected only in CG and not in other subcellular fractions; these findings indicate the localization of these particular basic residue aminopeptidase activities to secretory vesicles. The arginine and lysine aminopeptidase activities showed pH optima at 6.7 and 7.0, respectively. Km(app) values for the arginine and lysine aminopeptidase activities were 104 and 160 microM, respectively. Inhibition by the aminopeptidase inhibitors bestatin, amastatin, and arphamenine was observed for Arg-MCA and Lys-MCA cleaving activities. Inhibition by the metal ion chelators indicated that metalloproteases were involved; Co2+ stimulated the arginine aminopeptidase activity but was less effective in stimulating lysine aminopeptidase activity. In addition, the lysine aminopeptidase activity was partially inhibited by Ni2+ and Zn2+ (1 mM), whereas the arginine aminopeptidase activity was minimally affected. These results demonstrate the presence of related arginine and lysine thiol metalloaminopeptidase activities in CG that may participate in prohormone processing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422358     DOI: 10.1046/j.1471-4159.1998.70010153.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

1.  Reprint of: Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis.

Authors:  Hisatsugu Koshimizu; Taeyoon Kim; Niamh X Cawley; Y Peng Loh
Journal:  Regul Pept       Date:  2010-10-13

2.  Sequence-divergent units of the ABA-1 polyprotein array of the nematode Ascaris suum have similar fatty-acid- and retinol-binding properties but different binding-site environments.

Authors:  J Moore; L McDermott; N C Price; S M Kelly; A Cooper; M W Kennedy
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 3.  Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.

Authors:  Vivian Hook; Lydiane Funkelstein; Douglas Lu; Steven Bark; Jill Wegrzyn; Shin-Rong Hwang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 4.  Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides.

Authors:  Lydiane Funkelstein; Margery Beinfeld; Ardalan Minokadeh; James Zadina; Vivian Hook
Journal:  Neuropeptides       Date:  2010-11-02       Impact factor: 3.286

5.  Human cathepsin V protease participates in production of enkephalin and NPY neuropeptide neurotransmitters.

Authors:  Lydiane Funkelstein; W Douglas Lu; Britta Koch; Charles Mosier; Thomas Toneff; Laurent Taupenot; Daniel T O'Connor; Thomas Reinheckel; Christoph Peters; Vivian Hook
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

Review 6.  Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease.

Authors:  Vivian Hook; Lydiane Funkelstein; Jill Wegrzyn; Steven Bark; Mark Kindy; Gregory Hook
Journal:  Biochim Biophys Acta       Date:  2011-09-08

Review 7.  Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis.

Authors:  Hisatsugu Koshimizu; Taeyoon Kim; Niamh X Cawley; Y Peng Loh
Journal:  Regul Pept       Date:  2009-12-16

8.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter.

Authors:  Sukkid Yasothornsrikul; Doron Greenbaum; Katalin F Medzihradszky; Thomas Toneff; Richard Bundey; Ruthellen Miller; Birgit Schilling; Ivonne Petermann; Jessica Dehnert; Anna Logvinova; Paul Goldsmith; John M Neveu; William S Lane; Bradford Gibson; Thomas Reinheckel; Christoph Peters; Matthew Bogyo; Vivian Hook
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

9.  Proteolytic fragments of chromogranins A and B represent major soluble components of chromaffin granules, illustrated by two-dimensional proteomics with NH(2)-terminal Edman peptide sequencing and MALDI-TOF MS.

Authors:  Jean C Lee; Vivian Hook
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

10.  Cathepsin L participates in the production of neuropeptide Y in secretory vesicles, demonstrated by protease gene knockout and expression.

Authors:  Lydiane Funkelstein; Thomas Toneff; Shin-Rong Hwang; Thomas Reinheckel; Christoph Peters; Vivian Hook
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.